Autobahn Therapeutics launches with $76m Series B financing to develop next generation therapies for CNS disorders

This article was originally published here

Autobahn Therapeutics is launching to create the next generation of regenerative medicines to restore hope for people affected by CNS disorders. The company has completed a $76 million

The post Autobahn Therapeutics launches with $76m Series B financing to develop next generation therapies for CNS disorders appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply